Sciwind Biosciences
Peptide therapeutics (obesity/metabolic)
Privately held: no public share price · China
Assets
(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorPeptide | ObesityType 2 DiabetesOsteoarthritis | |
| Phase 2 | GLP-1 receptorPeptide | Obesity | |
| Phase 1 | GLP-1 receptorSmall molecule | Type 2 Diabetes |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (4)
January 2027 (1)
Est. primary completion 2027-01-05 · NCT07243171 · CT.gov ↗
What to watch
February 2027 (1)
Est. primary completion 2027-02-27 · NCT07073417 · CT.gov ↗
What to watch
September 2027 (1)
Est. primary completion 2027-09-03 · NCT07929298 · CT.gov ↗
What to watch
December 2027 (1)
Est. primary completion 2027-12-16 · NCT07387094 · CT.gov ↗
What to watch
2028 (3)
May 2028 (1)
Est. primary completion 2028-05-31 · NCT07734311 · CT.gov ↗
What to watch
June 2028 (2)
ecnoglutidePhase 3Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
Est. primary completion 2028-06-08 · NCT07836270 · CT.gov ↗
What to watch
Est. primary completion 2028-06-19 · NCT07434050 · CT.gov ↗
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.